SOUTH SAN FRANCISCO, Calif. -- (Business Wire)
Exelixis, Inc. (NASDAQ: EXEL) will release its first quarter 2013
financial results on Tuesday, May 7, 2013 after the markets close. The
announcement will be followed by a live webcast at 5:00 p.m. EDT/ 2:00
p.m. PDT. During the webcast, Exelixis management will discuss the
Company's financial results, financial outlook and development program
and plans for cabozantinib, and also provide a general business update.
The webcast may be accessed in the Event Calendar page under Investors &
Media at www.exelixis.com.
An archived replay of the webcast will be available on the Event
Calendar page under Investors & Media at www.exelixis.com
and via phone until 11:59 p.m. EDT on June 7, 2013. Access numbers for
the phone replay are: 888-286-8010 (domestic) and 617-801-6888
(international); the passcode is 84660665.
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on COMETRIQ™
(cabozantinib). Exelixis has also established a portfolio of other novel
compounds that it believes have the potential to address serious unmet
medical needs, many of which are being advanced by partners as part of
collaborations. For more information, please visit the company's web
site at www.exelixis.com.
Charles Butler, 650-837-7277
Source: Exelixis, Inc.
© 2018 Canjex Publishing Ltd. All rights reserved.